N-(1,3-diphenyl-1H-pyrazol-4-yl)-11-mercaptoundecanamide | 1220709-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(1,3-diphenyl-1H-pyrazol-4-yl)-11-mercaptoundecanamide
• 英文别名: N-(1,3-diphenylpyrazol-4-yl)-11-sulfanylundecanamide
• CAS: 1220709-79-4
• 化学式: C₂₆H₃₃N₃OS
• 分子量: 435.634
• InChiKey: DAPWSEDEJZAZHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  47.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  11-巯基十一烷酸 、 4-amino-1,3-diphenyl-1H-pyrazole 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以53%的产率得到N-(1,3-diphenyl-1H-pyrazol-4-yl)-11-mercaptoundecanamide
  参考文献：
  名称：

  Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas

  摘要：

  A series of novel 3,4-disubstituted pyrazoles were synthesized. The cytotoxicity against U87MG glioma cell line have been investigated in vitro and three of these compounds showed promising inhibitory activity on cell growth with an IC(50) lower than 90 mu M. AutoDock molecular docking into type I TGF-beta receptor (TGF-beta-RI; PDB: 1py5) has been done for lead optimization of the mentioned compounds as potential TGF-beta-RI1 inhibitors. In particular, 3-aryl-4-amido pyrazole containing long omega-amino-aliphatic chain emerged as a good candidate for further optimization. Entrapment into targetable PEG-based micelles improved growth inhibition IC(50) values up to 100 nM and this could lead to a novel drug delivery strategy for treating glioblastoma. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.01.014

文献信息

• Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas
  作者：Mauro Comes Franchini、Bianca Flavia Bonini、Carlo Maurizio Camaggi、Denis Gentili、Annalisa Pession、Monica Rani、Elena Strocchi

  DOI：10.1016/j.ejmech.2010.01.014

  日期：2010.5

  A series of novel 3,4-disubstituted pyrazoles were synthesized. The cytotoxicity against U87MG glioma cell line have been investigated in vitro and three of these compounds showed promising inhibitory activity on cell growth with an IC(50) lower than 90 mu M. AutoDock molecular docking into type I TGF-beta receptor (TGF-beta-RI; PDB: 1py5) has been done for lead optimization of the mentioned compounds as potential TGF-beta-RI1 inhibitors. In particular, 3-aryl-4-amido pyrazole containing long omega-amino-aliphatic chain emerged as a good candidate for further optimization. Entrapment into targetable PEG-based micelles improved growth inhibition IC(50) values up to 100 nM and this could lead to a novel drug delivery strategy for treating glioblastoma. (C) 2010 Elsevier Masson SAS. All rights reserved.